JP2010518168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518168A5 JP2010518168A5 JP2009549685A JP2009549685A JP2010518168A5 JP 2010518168 A5 JP2010518168 A5 JP 2010518168A5 JP 2009549685 A JP2009549685 A JP 2009549685A JP 2009549685 A JP2009549685 A JP 2009549685A JP 2010518168 A5 JP2010518168 A5 JP 2010518168A5
- Authority
- JP
- Japan
- Prior art keywords
- tramadol
- inhibitor
- pharmaceutically acceptable
- pde5
- acceptable form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 36
- 229960004380 tramadol Drugs 0.000 claims 29
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 29
- 239000000463 material Substances 0.000 claims 25
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 24
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 24
- 238000000034 method Methods 0.000 claims 22
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 18
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 17
- 239000003638 chemical reducing agent Substances 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 9
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 8
- 229960002639 sildenafil citrate Drugs 0.000 claims 8
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 8
- 229960000835 tadalafil Drugs 0.000 claims 8
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 5
- FBCDRHDULQYRTB-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;trihydrate;hydrochloride Chemical compound O.O.O.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 FBCDRHDULQYRTB-UHFFFAOYSA-N 0.000 claims 4
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 4
- 229960003086 naltrexone Drugs 0.000 claims 4
- 239000003401 opiate antagonist Substances 0.000 claims 4
- 229960003310 sildenafil Drugs 0.000 claims 4
- 229960002381 vardenafil Drugs 0.000 claims 4
- 229960001540 vardenafil hydrochloride Drugs 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 206010036596 premature ejaculation Diseases 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 230000036299 sexual function Effects 0.000 claims 2
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims 1
- 206010002652 Anorgasmia Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88938007P | 2007-02-12 | 2007-02-12 | |
| US60/889,380 | 2007-02-12 | ||
| PCT/US2008/053722 WO2008100933A2 (en) | 2007-02-12 | 2008-02-12 | Reducing side effects of tramadol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518168A JP2010518168A (ja) | 2010-05-27 |
| JP2010518168A5 true JP2010518168A5 (enExample) | 2012-01-26 |
| JP5550101B2 JP5550101B2 (ja) | 2014-07-16 |
Family
ID=39690762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549685A Expired - Fee Related JP5550101B2 (ja) | 2007-02-12 | 2008-02-12 | トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20080261991A1 (enExample) |
| EP (2) | EP2114147B9 (enExample) |
| JP (1) | JP5550101B2 (enExample) |
| KR (2) | KR20130122023A (enExample) |
| CN (1) | CN101674728A (enExample) |
| AU (1) | AU2008216363B2 (enExample) |
| BR (1) | BRPI0807281A2 (enExample) |
| CA (1) | CA2677691C (enExample) |
| DK (1) | DK2114147T3 (enExample) |
| ES (1) | ES2384127T3 (enExample) |
| MX (1) | MX2009008511A (enExample) |
| NZ (1) | NZ579170A (enExample) |
| PL (1) | PL2114147T3 (enExample) |
| SG (1) | SG178775A1 (enExample) |
| WO (1) | WO2008100933A2 (enExample) |
| ZA (1) | ZA200906187B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579169A (en) * | 2007-02-12 | 2012-05-25 | Dmi Biosciences Inc | Treatment of comorbid premature ejaculation and erectile dysfunction using tramadol and a phosphodiesterase (pde) inhibitor |
| DK2114147T3 (da) * | 2007-02-12 | 2012-06-25 | Dmi Biosciences Inc | Reduktion af bivirkninger af tramadol |
| US8202525B2 (en) | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| WO2012142273A1 (en) | 2011-04-12 | 2012-10-18 | Revogenex Inc. | Intravenous administration of tramadol |
| WO2015134695A1 (en) * | 2014-03-07 | 2015-09-11 | Vyrix Pharmaceuticals, Inc. | Method of mitigating the side effects of a phosphodiesterase type v inhibitor in a subject |
| US20160228485A1 (en) * | 2015-02-11 | 2016-08-11 | Latasha M. Watts | Skin medicating system |
| US9980900B2 (en) | 2015-12-22 | 2018-05-29 | Revogenex Ireland Ltd | Intravenous administration of tramadol |
| US9693949B1 (en) | 2015-12-22 | 2017-07-04 | Revogenex Ireland Ltd | Intravenous administration of tramadol |
| US10022321B2 (en) | 2016-06-30 | 2018-07-17 | Revogenex Ireland Ltd. | Intravenous administration of tramadol |
| WO2020006606A1 (en) * | 2018-07-05 | 2020-01-09 | Helium 3 Resources Pty Ltd | A pharmaceutical composition and method of use of same |
| EP4188329A4 (en) | 2020-07-29 | 2024-08-14 | Kydes Pharmaceuticals, LLC | PHARMACEUTICAL FORMULATIONS CONTAINING TADALAFIL |
| US11504332B2 (en) | 2021-03-23 | 2022-11-22 | Vk Research Associates Inc. | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3830934A (en) * | 1967-07-27 | 1974-08-20 | Gruenenthal Chemie | Analgesic and antitussive compositions and methods |
| US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
| US4127118B1 (en) * | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| ES2124225T3 (es) | 1990-04-25 | 1999-02-01 | Vivus Inc | Tratamiento de la disfuncion erectil. |
| US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5151448A (en) * | 1991-07-12 | 1992-09-29 | Crenshaw Roger T | Method for treating premature ejaculation |
| HU219332B (hu) * | 1991-09-06 | 2001-03-28 | Mcneilab Inc | Transz-(+)-2-[(dimetil-amino)-metil]-1-(3-metoxi-fenil)-ciklohexanolt és acetaminofent tartalmazó szinergetikus gyógyszerkészítmények |
| US5223541A (en) | 1991-09-13 | 1993-06-29 | Mcneilab, Inc. | Tramadol n-oxide material, enantiomers and compositions thereof, and their use |
| US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
| US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US20010006967A1 (en) | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
| NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| DE4329794C2 (de) | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US5861431A (en) | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
| GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| DE19601744C2 (de) * | 1996-01-19 | 1998-04-16 | Gruenenthal Gmbh | Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol |
| DE19601745C1 (de) * | 1996-01-19 | 1997-10-09 | Gruenenthal Gmbh | Verfahren zur Racematspaltung von Tramadol |
| IL119121A (en) * | 1996-08-22 | 2000-11-21 | Chemagis Ltd | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| PL335619A1 (en) * | 1997-03-11 | 2000-05-08 | Darwin Discovery Ltd | Dosage forms including separate parts containing r and s enantiomers |
| JP4085433B2 (ja) * | 1997-04-11 | 2008-05-14 | 日本新薬株式会社 | 頻尿・尿失禁治療剤 |
| US6037360A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
| US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| TR200001338T2 (tr) * | 1997-11-12 | 2000-08-21 | Bayer Aktiengesellschaft | 2-Fenil-ikameli imidazotriazinonlar |
| DK1685839T3 (da) * | 1997-12-22 | 2013-06-24 | Euro Celtique Sa | Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist |
| US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| CN1204890C (zh) * | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
| US6339826B2 (en) * | 1998-05-05 | 2002-01-15 | International Business Machines Corp. | Client-server system for maintaining a user desktop consistent with server application user access permissions |
| GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
| US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
| US6403605B1 (en) * | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| CN1329590A (zh) | 1998-12-02 | 2002-01-02 | 达尔文发现有限公司 | 治疗产品及其应用 |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| US6943166B1 (en) * | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
| US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| US20030055070A1 (en) * | 1999-07-01 | 2003-03-20 | Wilma Harrison | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction |
| US6821975B1 (en) * | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
| US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| US6297286B1 (en) | 1999-11-09 | 2001-10-02 | Darwin Discovery, Ltd. | Therapeutic use and formulation |
| US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| CN1289071C (zh) * | 2001-03-16 | 2006-12-13 | Dmi生物科学公司 | 曲马朵物质在制备用于延缓男性射精的药物中的用途 |
| CN1592609A (zh) * | 2001-05-11 | 2005-03-09 | 恩德制药公司 | 抗滥用阿片样物质剂型 |
| WO2003013525A1 (en) * | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
| US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| WO2003042216A1 (en) * | 2001-11-09 | 2003-05-22 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
| AU2003217669A1 (en) * | 2002-02-25 | 2003-09-09 | Smithkline Beecham Corporation | A method of recuding anti-neoplastic agent induced side effects |
| US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| US20050054688A1 (en) * | 2003-08-08 | 2005-03-10 | Pfizer Inc | Selective serotonin reuptake inhibitors in the treatment of disease |
| US20060149480A1 (en) * | 2004-02-26 | 2006-07-06 | Lundeen James E | Method of making combination medicament and medicament made thereby |
| JP4475098B2 (ja) * | 2004-11-02 | 2010-06-09 | ソニー株式会社 | 記憶素子及びその駆動方法 |
| US20090111837A1 (en) * | 2005-03-01 | 2009-04-30 | Peter Cox | Use of pde7 inhibitors for the treatment of neuropathic pain |
| JP5528705B2 (ja) * | 2005-12-13 | 2014-06-25 | トリニティ ラボラトリーズ インコーポレイテッド | ヒトにおける早漏を治療するための方法 |
| US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
| NZ579169A (en) * | 2007-02-12 | 2012-05-25 | Dmi Biosciences Inc | Treatment of comorbid premature ejaculation and erectile dysfunction using tramadol and a phosphodiesterase (pde) inhibitor |
| DK2114147T3 (da) * | 2007-02-12 | 2012-06-25 | Dmi Biosciences Inc | Reduktion af bivirkninger af tramadol |
| WO2008131256A1 (en) * | 2007-04-19 | 2008-10-30 | Trinity Laboratories Inc. | Improved treatments for premature ejaculation in humans |
-
2008
- 2008-02-12 DK DK08729655.4T patent/DK2114147T3/da active
- 2008-02-12 WO PCT/US2008/053722 patent/WO2008100933A2/en not_active Ceased
- 2008-02-12 AU AU2008216363A patent/AU2008216363B2/en not_active Ceased
- 2008-02-12 SG SG2012009536A patent/SG178775A1/en unknown
- 2008-02-12 CA CA2677691A patent/CA2677691C/en not_active Expired - Fee Related
- 2008-02-12 KR KR1020137027225A patent/KR20130122023A/ko not_active Withdrawn
- 2008-02-12 EP EP08729655.4A patent/EP2114147B9/en active Active
- 2008-02-12 EP EP12167725A patent/EP2486921A1/en not_active Withdrawn
- 2008-02-12 PL PL08729655T patent/PL2114147T3/pl unknown
- 2008-02-12 MX MX2009008511A patent/MX2009008511A/es active IP Right Grant
- 2008-02-12 JP JP2009549685A patent/JP5550101B2/ja not_active Expired - Fee Related
- 2008-02-12 KR KR1020097018879A patent/KR101497509B1/ko active Active
- 2008-02-12 US US12/029,973 patent/US20080261991A1/en not_active Abandoned
- 2008-02-12 NZ NZ579170A patent/NZ579170A/en not_active IP Right Cessation
- 2008-02-12 CN CN200880011692A patent/CN101674728A/zh active Pending
- 2008-02-12 BR BRPI0807281-7A2A patent/BRPI0807281A2/pt not_active IP Right Cessation
- 2008-02-12 ES ES08729655T patent/ES2384127T3/es active Active
-
2009
- 2009-09-07 ZA ZA2009/06187A patent/ZA200906187B/en unknown
-
2011
- 2011-09-28 US US13/247,450 patent/US20120018333A1/en not_active Abandoned
-
2013
- 2013-08-19 US US13/970,198 patent/US20130338166A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2677691A1 (en) | Reducing side effects of tramadol | |
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| JP2009280621A5 (enExample) | ||
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| FI3518933T4 (fi) | Menetelmiä kohtumyooman ja endometrioosin hoitamiseksi | |
| JP2007533686A5 (enExample) | ||
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| JP2019503365A5 (enExample) | ||
| UA93543C2 (ru) | Применение дозированной лекарственной формы, которая содержит оксикодон и налоксон | |
| JP2016539156A5 (enExample) | ||
| JP2010536849A5 (enExample) | ||
| SI2529622T1 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2013542246A5 (enExample) | ||
| JP2010535805A5 (enExample) | ||
| WO2007123865A3 (en) | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | |
| HRP20131233T1 (hr) | Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor | |
| JP2010518167A5 (ja) | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット | |
| WO2014027981A3 (en) | Effervescent tablet formulations of dapoxetine and a pde5 inhibitor | |
| RU2006143652A (ru) | Фармацевтические композиции и их применение в лечении женской сексуальной дисфункции | |
| NZ719087A (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| JP2009518415A5 (enExample) | ||
| CA2677690A1 (en) | Treatment of comorbid premature ejaculation and erectile dysfunction | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| JP2015521647A5 (enExample) |